The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Open accessAbstract
Background New research criteria for preclinical Alzheimer's disease have been proposed, which include stages for cognitively normal individuals with abnormal amyloid markers (stage 1), abnormal amyloid and neuronal injury markers (stage 2), or abnormal amyloid and neuronal injury markers and subtle cognitive changes (stage 3). We aimed to investigate the prevalence and long-term outcome of preclinical Alzheimer's disease according to these criteria.Methods Participants were cognitively normal (clinical dementia rating [CDR]=0) community-dwelling volunteers aged at least 65 years who were enrolled between 1998 and 2011 at the Washington University School of Medicine (MO, USA). CSF amyloid-β1-42 and tau concentrations and a memory composite score were used to classify participants as normal (both markers normal), preclinical Alzheimer's disease stage 1-3, or suspected non-Alzheimer pathophysiology (SNAP, abnormal injury marker without abnormal amyloid marker). The primary outcome was the proportion of participants in each preclinical AD stage. Secondary outcomes included progression to CDR at least 0·5, symptomatic Alzheimer's disease (score of at least 0·5 for memory and at least one other domain and cognitive impairments deemed to be due to Alzheimer's disease), and mortality. We undertook survival analyses using subdistribution and standard Cox hazards models and linear mixed models.Findings Of 311 participants, 129 (41%) were classed as normal, 47 (15%) as stage 1, 36 (12%) as stage 2, 13 (4%) as stage 3, 72 (23%) as SNAP, and 14 (5%) remained unclassified. The 5-year progression rate to CDR at least 0·5, symptomatic Alzheimer's disease was 2% for participants classed as normal, 11% for stage 1, 26% for stage 2, 56% for stage 3, and 5% for SNAP. Compared with individuals classed as normal, participants with preclinical Alzheimer's disease had an increased risk of death after adjusting for covariates (hazard ratio 6·2, 95% CI 1·1-35·0; p=0·040).Interpretation Preclinical Alzheimer's disease is common in cognitively normal elderly people and is associated with future cognitive decline and mortality. Thus, preclinical Alzheimer's disease could be an important target for therapeutic intervention.Funding National Institute of Aging of the National Institutes of Health (P01-AG003991, P50-AG05681, P01-AG02676), Internationale Stichting Alzheimer Onderzoek, the Center for Translational Molecular Medicine project LeARN, the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, and the Charles and Joanne Knight Alzheimer Research Initiative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial studies in this emerging area have identified subgroups of older adults with subtle cognitive decline that do not conform to expected patterns and investigators have designated them as Suspected Non-Alzheimer Pathology (SNAP) and Unclassified groups [51, 52].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rate of cognitive decline is significantly greater for cognitively impaired and CU individuals who have abnormalities in both an amyloid biomarker and a second biomarker type (which could be CSF T-tau or P-tau, atrophy, or hypometabolism) in comparison to individuals who have neither or only one of these biomarker abnormalities [30–35,39,40,42–45].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the combination of an abnormal MRI, CSF T-tau, or FDG PET study with an abnormal amyloid biomarker provides much more powerful prediction of future cognitive decline [30–35,39,40,42–45] than an abnormal amyloid study alone.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“longitudinal studies have demonstrated that soluble p-tau and t-tau are increased already in preclinical disease (e.g., no cognitive impairment but evidence of AD pathology).5,6”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Attempts to quantify the duration of AD should be age-specific, because age imposes the greatest risk for both dementia and mortality, and take into account APOE genotype, sex, and cerebrospinal fluid (CSF) tau levels [4, 6, 10-12].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationA Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationEveritt, B. S. (2001) · Psychology Press eBooks · doi:10.4324/9781410605542-11 · Cited by 6,877
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citation
Cited by
Sorted by citations
Items 501–564 of 564
Hiltunen, M. (2014) · Työväentutkimus Vuosikirja
Vellas, B. J., & Oustric, S. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.005
New Frontiers in Alzheimer's Disease Diagnosis
Llorens, F., Nuhn, S., Peter, C., Zerr, I., & Stoeck, K. (2015) · InTech eBooks · doi:10.5772/59652 · Cited by 1
“Investigations of patients with genetic AD have demonstrated already 15 years prior to the onset of dementia significant pathological alterations in distinct biomarkers [211, 212].”
BackgroundInterview with Dr John Morris, 28 February 2013
Katz, S., & Peters, K. R. (2014) · Dementia · doi:10.1177/1471301214562142
Kan preklinisk Alzheimers sykdom oppdages hos friske eldre?
Rosness, T. A. (2014) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.1462
Preclinical Alzheimer Disease Prevalence and Outcomes
Matthews, B. R. (2013) · Journal watch · doi:10.1056/nejm-jw.na32357
Cognitive and Functional Considerations in Alzheimer’s Disease Diagnosis
Glenn, M., Mace, L. C., & Moelter, S. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00002-7
The Path of Alzheimer’s disease
Jansen, W. J. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161125wj
Li, X., Ng, K. P., Ba, M., Rosa‐Neto, P., & Gauthier, S. G. (2016) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_6-1
Review Article Tau: From research to clinical development
Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., Goedert, M., Mandelkow�, E., Mandelkow, E., Miller, D. S., et al. (2016)
Self-citationBerkowitz, L. E. (2017) · UNM’s Digital Repository (University of New Mexico)
Pusil, S. A. (2018) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.50766
Neuroimaging Advances in Preclinical Alzheimers disease
Sheng, C., Huang, Y. M., Li, H., Sun, Y., Chen, Q., Ma, C., Liu, F., & Han, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000508
“Current studies have indicated that the combination of amyloid and tau pathology may be most suitable in stratifying individuals with the highest risk of conversion to AD [14], while individuals exhibit an isolated brain amyloidopathy or tauopathy have relatively lower risk.”
BackgroundSpatial Navigation Ability as a Predictor of Increased Clinical Impairment
Hindershott, T. (2019) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/mz46-3168
“1 Chapter 1: Introduction There is a current research emphasis on developing cognitive measures that are sensitive to preclinical Alzheimer disease (AD), which is associated with an increased risk of developing symptomatic AD (Jack et al., 2018; Vos et al., 2013).”
BackgroundClinical and biomarker changes in sporadic Alzheimer’s diseasePreprint
Zhuo, J., Zhang, Y., Liu, B., Liu, Y., Zhou, X. A., Bartlett, P. F., Jiang, T., & Initiative, T. A. D. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.08.084293
ROLE OF PATHOGENIC PROTEINS AND CHRONIC INFLAMMATION IN THE OCCURRENCE OF ALZHEIMER'S DISEASE
Denysenko, A., Haikova, O. O., & Moskalenko, R. (2020) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2020;8(4):475-490
Schleicher, E. M. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8990
Schweiger, A., Rodebaugh, T. L., Lenze, E. J., Keenoy, K., Hassenstab, J. J., Kloeckner, J., Gettinger, T. R., & Nicol, G. E. (2022) · doi:10.2196/preprints.39233
Self-citationNeuroimaging and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
Gordon, B. A., Vos, S. J. B., & Fagan, A. M. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0052
Self-citationNovel perspectives from existing data on early Alzheimer’s disease pathology and dementia care use
Janssen, O. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220617oj
Het gelijk van Dr. Alois Alzheimer
Verhey, F. R. J. (2022) · doi:10.26481/spe.20220513fv
New Therapeutic Approaches for Sensory Symptoms in Alzheimer’s Disease
Reddy, C., & Madureira, M. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3793
Digital tools to support dementia diagnosis
van Gils, A. M. (2024) · doi:10.5463/thesis.750
Chang, Y., Xu, L., Gao, C., Khairi, N. M., Gore, J. C., Landman, B. A., & Gao, Y. (2025) · SPIE Medical Imaging: Clinical and Biomedical Imaging · doi:10.1117/12.3046835
Paulsen, A., Driscoll, I. F., Breidenbach, B. M., Glittenberg, M., Lose, S., Ma, Y., Sager, M. A., Carlsson, C., Gallagher, C., Hermann, B. P., et al. (2025) · medRxiv · doi:10.1101/2025.03.03.25323245
What is “SNAP”? Historical Review of the Diagnosis of Alzheimer’s Disease
Ishihara, K. (2025) · Higher Brain Function Research · doi:10.2496/hbfr.45.11
Alzheimer Disease Prediction Through Guided Predictive Modeling With Machine Learning
Alfayat, M. P., & Whardana, A. K. (2025) · JEECS (Journal of Electrical Engineering and Computer Sciences) · doi:10.54732/jeecs.v10i1.5
“The dataset was partitioned into two subsets: 80% allocated for training and 20% for validation [13].”
Brennan, G. S., Thompson, T., Oliveri, H., Vinje, V., Ringstad, G. A., Eide, P. K., Goriely, A., & Rognes, M. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.03.657596
Chen, C., & Babulal, G. M. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251365636
“19,20 As a multi-task digital biomarker, driving requires more than just the cognitive abilities assessed by traditional cognitive tests.”
Epidemiological studies on heavy metal exposure and neurodegeneration
Choudhury, D. R., & Kumar, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36575-1.00001-7
He, J., He, J., Zhang, W., Wang, Y., Wu, Y., Wang, X., Zhao, J., Chu, X., & Wang, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389239
Kas, A., & Bombois, S. (2025) · Médecine Nucléaire · doi:10.1016/j.mednuc.2025.09.007
Huszár, Z., Engh, M. A., Pavlekovics, M., Sato, T., Steenkamp, Y., Hanseeuw, B. J., Terebessy, T., Molnár, Z., Hegyi, P., & Csukly, G. (2024) · Figshare · doi:10.6084/m9.figshare.26705691
Zavecz, Z., Shah, V. D., Murillo, O. G., Vallat, R., Mander, B. A., Winer, J. R., Jagust, W. J., & Walker, M. P. (2024) · Figshare · doi:10.6084/m9.figshare.26584560
Barthélemy, N. R., Bateman, R. J., Hirtz, C., Marin, P., Bécher, F., Sato, C., Gabelle, A., & Lehmann, S. (2020) · Figshare · doi:10.6084/m9.figshare.11998815
Barthélemy, N. R., Bateman, R. J., Hirtz, C., Marin, P., Bécher, F., Sato, C., Gabelle, A., & Lehmann, S. (2020) · Figshare · doi:10.6084/m9.figshare.11998812
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.29.696818
“…by intracellular accumulation of hyperphosphorylated tau (hTau) protein into neurofibrillary tangles (NFTs), both of which contribute to neuronal and synaptic loss and clinical manifestations of cognitive dysfunction and memory impairment (Bateman et al., 2012; Jack et al., 2013; Vos et al., 2013).”
The “Hyperactive” Phenotype of Alzheimer’s Disease
Horváth, A., & Kamondi, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-95878-6_8
Predicting MCI Conversion Status Using Baseline Neuroimaging Scans and Genetics Variations
Yang, Y. X., Shang, M., Wang, Y., Zhang, J., Li, H., Wang, Y., & Du, L. (2025) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm66473.2025.11356099
“Magnetic Resonance Imaging (MRI) [6] and Positron Emission Tomography (PET) [7] are beneficial for the prediction of MCI conversion because the neuropathological progression may begin many years prior to the manifestation of clinical symptoms [8].”
Sleep-Wake Transitions Are Impaired in the AppNL-G-F Mouse Model of Early Onset Alzheimer’s DiseasePreprint
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2026) · eLife · doi:10.7554/elife.110240.1
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2026) · eLife · doi:10.7554/elife.110240 · Cited by 1
Will Precision Medicine Still Require Neuropsychiatric Phenotypes?
Ebmeier, K. P., & Valkanova, V. (2026) · Neurology · doi:10.1212/wnl.0000000000214820
Şahin, H., & Şahin, H. (2026) · Clinical and Experimental Health Sciences · doi:10.33808/clinexphealthsci.1745629
Sepulveda-Diaz, J. E. (2013) · theses.fr (ABES) · doi:10.70675/56c42bcbz41dfz432bzbb78z77110b373285
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
Epelbaum, S. (2015) · theses.fr (ABES) · doi:10.70675/ea81e5c2z5032z4474z9f96z59f62125a629
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Vorkapich, A., Mustafa, A., Flores, A., Zarbalis, K. S., & Giulivi, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-43314-0
“…our findings, we compared DEPs from Wdfy3 +/lacZ mouse cortex with publicly available human PD brain and cerebrospinal fluid (CSF) proteomic datasets, including substantia nigra (PXD037684), prefrontal cortex (PXD030142), frontal cortex (PXD007160), and CSF (PPI_177) (Supplementary Tables 17–19).”
La place des biomarqueurs dans les essais de prévention de la maladie d'Alzheimer
Delrieu, J. (2021) · theses.fr (ABES) · doi:10.70675/2b5f4719z01f9z4376z9dabzd5a185dc4d79
Li, J., Lian, T., Guo, P., Li, J., Qi, J., He, M.-Y., Dong-mei, L., Zhang, Y.-N., Gai-fen, L., Huang, Y., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1737524
“As the core biomarker of AD, it has been found that P-tau181 in CSF predicted the cognitive decline in patients at preclinical, MCI and dementia stages, and was associated with the severity of AD (Vos et al., 2013).”
McKenna, M., Torous, J. B., Rozenblit, E., Flathers, M., Ryan, S., Byun, A. J. S., & Lim, C. (2026) · JMIR Research Protocols · doi:10.2196/93259
“In the United States, 7.2 million people have Alzheimer disease (AD) [1], a slowly progressive neurodegenerative disease with the deterioration from cognitively normal to dementia taking years to decades [2].”
InfluentialReal-world clinical profile of individuals with cerebrospinal fluid Aβ – /pTau181 +
Keret, O., Xia, T., Wilkins, S., Ncube, L., Smaw, B., Xiong, Y., Gandy, S., Pereira, A., Naasan, G., & Elahi, F. M. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261445561
“5,37 More recent work, however, emphasizes that SNAP represents a heterogeneous group of A β negative pathologies.”
Rizzo, M., Oomens, J. E., Jansen, W. J., Visser, P. J., & Vos, S. J. B. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261453099 · Cited by 1
Self-citationMagnani, A., Bassi, L., Pierobon, A., Mancini, D., Torlaschi, V., Maestri, R., Chimento, P., Fundarò, C., & Maffoni, M. (2026) · Brain Sciences · doi:10.3390/brainsci16060582
“Importantly, this continuum should be carefully interpreted as it can be modulated by interacting factors including cognitive reserve, medical comorbidities, lifestyle, and psychological health [3,4,8,15,16].”
Wu, J., Fang, T., Lv, X., Wang, Y., Gao, F., Shen, Y., Cheng, Z., & Shi, J. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70949
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2026) · eLife · doi:10.7554/elife.110240.2
Levine, C. M., Caggiano, C., Anderson, T., Kelberman, M. A., Weinshenker, D., Lail, H. L., Wanders, D., Bangasser, D. A., Kanoski, S. E., & Parent, M. B. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06014-4
“This pathology includes elevated Aβ and changes in tau that often go undetected until mild cognitive impairment (MCI) appears during the prodromal stage, which in turn lasts until frank dementia emerges during the clinical stage [8–13].”
Colitta, A., Mazzarone, T., Corsi, S., Petrozzi, L., Mengozzi, A., Chicca, M. D., Sessa, M. R., Bacciardi, E., Virdis, A., Monzani, F., et al. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09216-9
“Notably, this longitudinal association with adverse health outcomes extends to preclinical dementia [24, 25].”
Shrinking of Extracellular Space During Metabolic Stress Accelerates Amyloid-β Aggregation
Oliveira, L. F. D., Karunarathne, K., Zona, D., Muschol, M., & Ullah, G. (2026) · Biomolecules · doi:10.3390/biom16071053
Le concept de sujet à risque dans la maladie d’Alzheimer
Villain, N. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.06.015
Bayly, H., Salvati, L. R., Lenio, S., Mez, J., Alosco, M. L., & Tripodis, Y. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100081
“A substantial proportion of amyloid positive individuals exhibit slow, heterogenous, or negligible cognitive decline over several years [8 – 10].”
Botelho, C. V., Carneiro, A. A. M., Regadas, C. M., Cavalcante, C., Ribeiro, I., Rabelo, S., Araujo, V., Ferreira, G., Iepsen, B. D., & Frota, N. A. F. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261494512
Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial
Valls-Pedret, C., Sala-Vila, A., Serra-Mir, M., Corella, D., de la Torre, R., Martínez-González, M. Á., Martínez-Lapiscina, E. H., Fitó, M., Pérez-Heras, A., Salas-Salvadó, J., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1668 · Cited by 952
Metadata
- Authors
- Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M.
- Affiliations
- Maastricht University (NL)
- Washington University in St. Louis (US)
- Corresponding author
- Vos, Stephanie JB
- Fagan, Anne M
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 12
- Issue
- 10
- Pages
- 957-965
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC3904678
- OpenAlex
- W2096063777
- Cited by
- 564
- References
- 45
- Citations by year
- 2026: 20 · 2025: 37 · 2024: 30 · 2023: 17 · 2022: 40 · 2021: 39 · 2020: 45 · 2019: 54 · 2018: 63 · 2017: 54 · 2016: 53 · 2015: 52 · 2014: 52 · 2013: 7
- FWCI
- 38.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Mayo Clinic
- Center for Translational Molecular Medicine
- National Institute on Aging (P 50 AG05681, P50AG005681, P01AG003991, U19AG032438, P01-AG02676, P01AG026276)
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK094982)
- National Institute of Neurological Disorders and Stroke (P30NS057105)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- preclinical Alzheimer's disease, amyloid-beta 42, tau protein, cerebrospinal fluid biomarkers, cognitive decline, conversion to dementia, mortality, prevalence, cognitively normal elderly, Alzheimer's disease staging, community-dwelling older adults
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Peptide Fragments, Psychiatric Status Rating Scales, Severity of Illness Index, Prevalence, Survival Analysis, Amyloid beta-Peptides, tau Proteins, Disease Progression, Memory, Episodic, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
